EHA 2024 | APOLLO: ATO-ATRA versus standard ATRA + chemotherapy for patients with newly diagnosed high-risk APL
Uwe Platzbecker
• 14 Jun 2024
In this presentation, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, shares the first results from the Phase III APOLLO trial (NCT0268840), which compared arsenic trioxide plus all-trans retinoic acid (ATO-ATRA) to the standard of care (SoC) of ATRA plus chemotherapy for the treatment of patients with newly diagnosed, high-risk acute promyelocytic leukemia (APL). This press briefing took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
